article thumbnail

Rare Metabolic Disease That Leads to Childhood Obesity Gets Its First FDA-Approved Drug

MedCity News

Soleno Therapeutics Vykat XR is now FDA approved for treating hyperphagia, or excessive hunger, in patients with Prader-Willi syndrome. The once-daily pill is the first approved therapy for this rare disease, a leading cause of childhood obesity.

Leads 225
article thumbnail

Transforming Allergy Care: The Power of Advanced Diagnostics in Improving Patient Outcomes

MedCity News

Getting the correct food allergy diagnosis leads to increased diet diversity and potentially improved nutrition when suspected allergies are ruled out, making it critical to take the right diagnostic approach from the beginning.

Patients 164
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Private Equity Ownership Leads to Worse Patient Outcomes at Hospitals, Study Shows

MedCity News

Yet another study has been published showing that patients receiving care at PE-owned hospitals experienced a higher rate of hospital-acquired adverse events, like infections and falls, than patients receiving care at hospitals that are not PE-owned.

Patients 310
article thumbnail

GSK Multiple Myeloma Drug’s DREAMM Comeback Continues With Phase 3 Data at ASH

MedCity News

Results from the Phase 3 DREAMM-7 study show GSK drug Blenrep is helping multiple myeloma patients live longer compared to treatment with blockbuster Johnson & Johnson drug Darzalex. The post GSK Multiple Myeloma Drugs DREAMM Comeback Continues With Phase 3 Data at ASH appeared first on MedCity News.

FDA 287
article thumbnail

In gene therapy race, bluebird leads Vertex in activating treatment centers but trails in patient starts

Fierce Pharma

While Vertex leads in patient starts, bluebird has activated more treatment centers. It’s not an easy question to answer.

Leads 236
article thumbnail

Theseus Pharma Lays Off Staff, Explores Options Months After Toxicity Scuttles Lead Drug

MedCity News

Theseus Pharmaceuticals discontinued its former lead program in July following the report of dose-limiting toxicities in two patients. Though Theseus has other assets in its pipeline, it has decided to explore strategic alternatives with the goal of “maximizing shareholder value.”

Leads 287
article thumbnail

Streamlining the Patient Consent Process

MedCity News

Velatura, a leading multi-jurisdictional health information exchange and health data utility, along with Docusign, the leading intelligent agreement management solution that accelerates the process of doing business, have joined forces to streamline the process of obtaining and managing informed patient consent.

Patients 263